MedTrace Logo

Intravenous Magnesium in Patients Receiving Cisplatin

NCT04481672 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-01-11

No results posted yet for this study

Summary

This research study, is trying to determine the highest dose of magnesium that can be given safely to people with malignant mesothelioma receiving intraoperative chemotherapy with cisplatin who are at risk for acute kidney injury.

The name(s) of the study drug involved in this study is

* magnesium sulfate.

Conditions

Interventions

DRUG

Magnesium Sulfate

Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.

Sponsors & Collaborators

Principal Investigators

  • Shruti Gupta, MD, MPH · Brigham and Women's Hospital

  • David E. Leaf, MD, MMSc · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2021-12-30
Completion
2021-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04481672 on ClinicalTrials.gov